HTRA2 Defect: A Recognizable Inborn Error of Metabolism with 3-Methylglutaconic Aciduria as Discriminating Feature Characterized by Neonatal Movement Disorder and Epilepsy—Report of 11 Patients

Abstract

Neonatal-onset movement disorders, especially in combination with seizures, are rare and often related to mitochondrial disorders. 3-methylglutaconic aciduria (3-MGA-uria) is a marker for mitochondrial dysfunction. In particular, consistently elevated urinary excretion of 3-methylglutaconic acid is the hallmark of a small but growing group of inborn errors of metabolism (IEM) due to defective phospholipid remodeling or mitochondrial membrane-associated disorders (mutations in TAZ, SERAC1, OPA3, CLPB, DNAJC19, TMEM70, TIMM50). Exome/genome sequencing is a powerful tool for the diagnosis of the clinically and genetically heterogeneous mitochondrial disorders. Here, we report 11 individuals, of whom 2 are previously unpublished, with biallelic variants in high temperature requirement protein A2 (HTRA2) encoding a mitochondria-localized serine protease. All individuals presented a recognizable phenotype with neonatal- or infantile-onset neurodegeneration and death within the first month of life. Hallmark features were central hypopnea/apnea leading to respiratory insufficiency, seizures, neutropenia, 3-MGA-uria, tonus dysregulation, and dysphagia. Tremor, jitteriness, dystonia, and/or clonus were also common. HTRA2 defect should be grouped under the IEM with 3-MGA-uria as discriminating feature. Clinical characteristics overlap with other disorders of this group suggesting a common underlying pathomechanism. Urinary organic acid analysis is a noninvasive and inexpensive test that can guide further genetic testing in children with suggestive clinical findings.

Keywords

mitochondrial dysfunction - developmental delay - respiratory insufficiency - dystonia - tremor

• References

• 1 Ghaoui R, Sue CM. Movement disorders in mitochondrial disease. J Neurol 2018; 265 (05) 1230-1240
• 2 Wortmann SB, Kluijtmans LA, Rodenburg RJ. , et al. 3-Methylglutaconic aciduria--lessons from 50 genes and 977 patients. J Inherit Metab Dis 2013; 36 (06) 913-921
• 3 Wortmann SB, Duran M, Anikster Y. , et al. Inborn errors of metabolism with 3-methylglutaconic aciduria as discriminative feature: proper classification and nomenclature. J Inherit Metab Dis 2013; 36 (06) 923-928
• 4 Wortmann SB, Espeel M, Almeida L. , et al. Inborn errors of metabolism in the biosynthesis and remodelling of phospholipids. J Inherit Metab Dis 2015; 38 (01) 99-110
• 5 Wortmann SB, Ziętkiewicz S, Kousi M. , et al. CLPB mutations cause 3-methylglutaconic aciduria, progressive brain atrophy, intellectual disability, congenital neutropenia, cataracts, movement disorder. Am J Hum Genet 2015; 96 (02) 245-257
• 6 Mandel H, Saita S, Edvardson S. , et al. Deficiency of HTRA2/Omi is associated with infantile neurodegeneration and 3-methylglutaconic aciduria. J Med Genet 2016; 53 (10) 690-696
• 7 Oláhová M, Thompson K, Hardy SA. , et al. Pathogenic variants in HTRA2 cause an early-onset mitochondrial syndrome associated with 3-methylglutaconic aciduria. J Inherit Metab Dis 2017; 40 (01) 121-130
• 8 Kremer LS, Bader DM, Mertes C. , et al. Genetic diagnosis of Mendelian disorders via RNA sequencing. Nat Commun 2017; 8: 15824
• 9 Shahrour MA, Staretz-Chacham O, Dayan D. , et al; NISC Intramural Sequencing. Mitochondrial epileptic encephalopathy, 3-methylglutaconic aciduria and variable complex V deficiency associated with TIMM50 mutations. Clin Genet 2017; 91 (05) 690-696
• 10 Baldi C, Bertoli-Avella AM, Al-Sannaa N. , et al. Expanding the clinical and genetic spectra of NKX6-2-related disorder. Clin Genet 2018; 93 (05) 1087-1092
• 11 Merski M, Moreira C, Abreu RM. , et al. Molecular motion regulates the activity of the Mitochondrial Serine Protease HtrA2. Cell Death Dis 2017; 8 (10) e3119
• 12 Kilbride SM, Prehn JH. Central roles of apoptotic proteins in mitochondrial function. Oncogene 2013; 32 (22) 2703-2711
• 13 Vande Walle L, Lamkanfi M, Vandenabeele P. The mitochondrial serine protease HtrA2/Omi: an overview. Cell Death Differ 2008; 15 (03) 453-460
• 14 Chi CS, Lee HF, Tsai CR, Chen WS, Tung JN, Hung HC. Lactate peak on brain MRS in children with syndromic mitochondrial diseases. J Chin Med Assoc 2011; 74 (07) 305-309
• 15 Strauss KM, Martins LM, Plun-Favreau H. , et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet 2005; 14 (15) 2099-2111
• 16 Chen CM, Wu CH, Hsieh CH. , et al. HTRA2 variations in Taiwanese Parkinson's disease. J Neural Transm (Vienna) 2014; 121 (05) 491-498
• 17 Unal Gulsuner H, Gulsuner S, Mercan FN. , et al. Mitochondrial serine protease HTRA2 p.G399S in a kindred with essential tremor and Parkinson disease. Proc Natl Acad Sci U S A 2014; 111 (51) 18285-18290
• 18 Simón-Sánchez J, Singleton AB. Sequencing analysis of OMI/HTRA2 shows previously reported pathogenic mutations in neurologically normal controls. Hum Mol Genet 2008; 17 (13) 1988-1993
• 19 Tzoulis C, Zayats T, Knappskog PM. , et al. HTRA2 p.G399S in Parkinson disease, essential tremor, and tremulous cervical dystonia. Proc Natl Acad Sci U S A 2015; 112 (18) E2268
• 20 Renaud M, Marcel C, Rudolf G. , et al. A step toward essential tremor gene discovery: identification of extreme phenotype and screening of HTRA2 and ANO3. BMC Neurol 2016; 16 (01) 238
• 21 Martins LM, Morrison A, Klupsch K. , et al. Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol Cell Biol 2004; 24 (22) 9848-9862
• 22 Jones JM, Datta P, Srinivasula SM. , et al. Loss of Omi mitochondrial protease activity causes the neuromuscular disorder of mnd2 mutant mice. Nature 2003; 425 (6959): 721-727
• 23 Forstner R, Hoffmann GF, Gassner I. , et al. Glutaric aciduria type I: ultrasonographic demonstration of early signs. Pediatr Radiol 1999; 29 (02) 138-143